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ABSTRACT: Bromodomains have been pursued intensively over the past several years as emerging targets for the development of 
anti-cancer and anti-inflammatory agents. It has recently been shown that some kinase inhibitors are able to potently inhibit the 
bromodomains of BRD4. The clinical activity of PLK inhibitor BI-2536 and JAK2-FLT3 inhibitor TG101348 have been attributed 
to this unexpected poly-pharmacology, indicating that dual-kinase/bromodomain activity may be advantageous in a therapeutic 
context. However, for target validation and biological investigation, a more selective target profile is desired. Here we report that 
benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones, versatile ATP-site directed kinase pharmacophores utilized in the development of 
inhibitors of multiple kinases including a number of previously reported kinase chemical probes, are also capable of exhibiting po-
tent BRD4-dependent pharmacology.  Using a dual kinase-bromodomain inhibitor of the kinase domains of ERK5 and LRRK2, and 
the bromodomain of BRD4 as a case study, we define the structure-activity relationships required to achieve dual kinase/BRD4 
activity as well as how to direct selectivity towards inhibition of either ERK5 or BRD4. This effort resulted in identification of one 
of the first reported kinase-selective chemical probes for ERK5 (JWG-071), a BET selective inhibitor (JWG-115), and additional 
inhibitors with rationally designed polypharmacology (JWG-047, JWG-069).  Co-crystallography of seven representative inhibi-
tors with the first bromodomain of BRD4 demonstrate that distinct atropisomeric conformers recognize the kinase ATP-site and the 
BRD4 acetyl lysine binding site, and this conformational preferences is supported by rigid docking studies. 
INTRODUCTION 
BRD4 is a critical transcription co-activator protein that 
possesses two druggable acetyl lysine binding domains (bro-
modomains) targeting the protein to chromatin by binding 
acetylated histones.1 BRD4 is a master regulatory elongation 
factor, influencing function of CDK92, the kinase activity of 
which is essential to phosphorylate RNA Polymerase II to 
initiate transcription,3-5 and aberrant activity of BRD4 contrib-
utes to deregulated transcription, a hallmark of many cancers.6-
8 BRD4 has been actively pursued as an oncology drug target 
with at least six compounds that target the acetyl lysine bind-
ing pocket currently under clinical investigation.9 These selec-
tive BET inhibitors have demonstrated phenotypic effects 
against a broad range of cancer cell lines and in models of 
inflammation, atherosclerosis and male fertility.  
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Synergy between BRD4 inhibition and a multitude of ki-
nase inhibitors has also been identified in cancer (e.g. with 
FLT3-TKI10, rapamycin11 and CX-494512), providing a ra-
tionale for development of therapeutics with potent dual 
BRD4-kinase activity. 
Recently several groups have made the surprising discovery 
that many ATP-competitive kinase inhibitors can also bind 
potently to the acetyl-lysine binding domain of BRD4.13,14 
Kinase inhibitors based on at least 10 different scaffolds have 
been shown to inhibit the BRD4 bromodomains. The clinical 
activity of the PLK inhibitor BI-2536 and the JAK2-FLT3 
inhibitor TG101348 have been attributed to this unexpected 
poly-pharmacology, indicating that in a therapeutic context 
dual kinase-bromodomain activity may be desirable.  
However, due to its ubiquitous expression and central im-
portance to the regulation of transcription, uncharacterized 
off-target BRD4 activity in chemical probes is undesirable, as 
it complicates the connection between the target and any phe-
notypes observed. Characterization of the BRD4 activity of 
classical kinase inhibitor scaffolds, and the trends governing 
the selectivity profile are important for unraveling the phar-
macologically relevant targets for these compounds. To this 
end, extensive work has been invested in characterizing the 
factors governing the PLK and BRD4 activity of BI-2536 ana-
logs based on a privileged ATP-site targeting pyrido[2,3-d] 
pyrimidine core.15,16 
Here we characterize the SAR trends and structural basis for 
the kinase and bromodomain activity profile of the related 
benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones and use these 
rules to generate selective chemical probes for ERK5/LRRK2 
and BRD4, and to develop rationally designed dual kinase 
(ERK5/LRRK2)-BRD4 inhibitors. We also observed two dis-
tinct conformers exclusively recognize the kinase ATP-site 
and the BRD4 acetyl lysine-binding site and analyzed the in-
terconversion rate for conformers with large substituents. 
RESULTS AND DISCUSSION 
ERK5 inhibitors XMD11-50 (LRRK2-IN-1) and 
XMD17-26 are dual kinase-bromodomain inhibitors. 
Based on the privileged nature of the pyrido[2,3-d] pyrimidine 
core of BI-2536 as an ATP-site targeting scaffold, we had 
built combinatorial libraries of analogs with a ben-
zo[e]pyrimido-[5,4-b]diazepine-6(11H)-one scaffold for use in 
kinase inhibitor projects, resulting in the discovery of multiple 
kinase inhibitor tool compounds (Figure 1).17 In order to test if 
this series also inhibits BRD4, analogous to BI-2536, we per-
formed a BRD4 AlphaScreen assay of our kinase-biased 
chemical library (data not shown).18 Many diazepinones were 
found to be active. Importantly some hits from this screen are 
published “selective” kinase chemical probes,19-24 and there-
fore this result provides valuable insight into their observed 
pharmacology25,26 (Figure 1). These molecules represent a 
new class of dual kinase-bromodomain inhibitors.  
We chose to investigate the structure activity relationship 
(SAR) of this scaffold against both ERK5/LRRK2 and BRD4, 
using BRD4 hit compounds XMD11-50 (LRRK2-IN-1) and 
XMD17-26 (published as an ERK5 inhibitor) as chemical 
starting points, aiming to develop a selective ERK5 inhibitor. 
This was motivated by the dual kinase-bromodomain inhibi-
tion profile of the compounds (Figure 1), the lack of availabil-
ity of a selective ERK5 chemical probe, the poorly character-
ized biological function of ERK5, and the potential of ERK5 
as a cancer drug target.  Specifically, the MEK5/ERK5 path-
way has been reported to be activated and/or overexpressed 
during tumor development, metastasis and tumor angiogene-
sis. 27-29  
 
Figure 1. BRD4 (BD1) inhibition of published kinase chemical probes. Kinase IC50s are as previously published in references. BRD4 
IC50 values were measured by AlphaScreenTM binding assay and reported as the average of 2 replicates ± SE (conducted in Dana-
Farber Cancer Institute, top data) and as the average of 4 replicates ± SD (conducted in University of Oxford, bottom data). (+)-JQ1 
IC50s are 64 nM and 120 nM respectively. 
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We began by confirming the BRD4 activity of the hit kinase 
inhibitors using isothermal titration calorimetry (ITC) and 
differential scanning fluorimetry (DSF) (Table 1), using (+)-
JQ1 as a BRD4 positive control. These data were in good 
agreement with IC50 values measured by AlphaScreen. Both 
compounds show comparable potency to other well character-
ized dual kinase/bromodomain inhibitors. 13,14   
To understand how these compounds bind to BRD4-BD1, 
we determined X-ray co-crystal structures of BRD4-BD1 with 
both XMD11-50 and XMD17-26 to 1.2 Å and 1.6 Å resolu-
tion respectively. (Figure 2A, 2B and Supplemental Table 
1). Both XMD11-50 and XMD17-26 were clearly defined in 
the electron density maps and bound in the acetyl lysine bind-
ing pocket (Supplemental Figure 3).  The core of the ben-
zo[e]pyrimido- [5,4-b]diazepine-6(11H)-one scaffold is buried  
deeply in the pocket and mediates most direct interactions 
with the protein (Figure 2A, 2B). It forms two hydrogen 
bonds directly with the bromodomain, one with the side chain 
of conserved Asn140, the other with the carbonyl oxygen of 
Pro82. The N-methyl amide group in the diazipinone ring fills 
a hydrophobic cavity in a manner analogous to N-acetyl group 
of an acetylated lysine residue.30 Structural waters are usually 
conserved and mediate a ligand-bromodomain interaction. In 
the XMD11-50 structure, there are three key structural waters 
forming hydrogen bonds with the ligand directly, and bridging 
hydrogen-bond interactions with the side chains of Gln85 and 
Tyr97, the carbonyl oxygens of Pro86 and Gln85, and main 
chain nitrogen of Asn88 (Figure 2A). In addition, the meth-
oxyphenyl moiety of the aniline tail forms a hydrophobic in-
teraction with the WPF shelf in the ZA loop. The rest of the 
ligand tail consisting of the methyl-4-piperidine-4-yl pipera-
zine moiety is solvent exposed, which suggests that it is not 
essential for ligand-protein recognition. The structure of 
XMD17-26 shares the same core interactions observed in the 
XMD11-50 structure (Figure 2B). In addition, the WPF shelf 
forms a hydrophobic interaction with the cyclopentyl R1 sub-
stituent of XMD17-26. The more bulky cyclopentyl substitu-
ent also causes a shift in the conformation of the tricyclic ring 
system. As a result, different angles between the planes of the 
scaffold are observed for the two compounds in the X-ray 
structures (Figure 2 C).  
Modulating selectivity for BRD4, ERK5 and LRRK2. 
We initiated our studies with a systematic structure-activity 
relationship analysis of the R1 substitution (Table 2). The R1 
group influences the conformation of the 7-membered diaze-
pine ring and mediates steric and hydrophobic interactions 
with BRD4. Thus, we anticipated that R1 substitutions would 
affect BRD4 activity and result in different selectivity profiles 
against BRD4, ERK5 and LRRK2. The newly synthesized 
compounds were tested for their ability to inhibit ERK5 and 
LRRK2 in vitro kinase activities, ERK5 cellular activity in 
human HeLa cells, BRD4-BD1 binding affinity and BRD4 
cellular activity in the BRD4-dependant 797 NUT-midline 
carcinoma cells which harbors a BRD4-NUT fusion onco-
gene.31 Addition of progressively larger alkyl substituents at 
R1, from methyl (XMD11-50) to sec-butyl (JWG-071) result-
ed in gradually reduced binding affinity for BRD4 and 
LRRK2, but had almost no effect on ERK5 inhibition, which 
may be due to steric clashes with the αC-helix of BRD4, indi-
cating this position is a crucial hotspot for dialing out bromo-
domain targets while maintaining ERK5 kinase activity. All 
attempts to synthesize 3-pentyl substituted analogs to explore 
the effect of larger substituents at R1failed, possibly due to 
steric hindrance. Having identified a kinase class-selective 
compound, the kinome wide selectivity of JWG-071 was as-
sessed using the KinomeScan methodology (DiscoverX) 
across a panel of 468 human kinases at a concentration of 1 
µM. Only two kinases, ERK5 and DCAMKL2, were hits in 
this assay (Ambit scores of less than 10%, Supplemental 
Figure 4 and Supplemental data). This off-target kinase activi-
 
Figure 2. (A) X-ray structure of XMD11-50 bound to BRD4-BD1. (B) X-ray structure of XMD17-26 bound to BRD4-BD1. (C) 
Overlay of the two compounds highlighting the different angular configuration of the diazipinone ring system.  
Table 1. Evaluation of initial BRD4 hits. 
Compound ID IC50 (nM)a IC50 (nM)b Kd (nM)c Tm (C)d 
XMD11-50 
(LRRK2-IN-1) 
703 ± 17 1040  180 192  28 2.1  0.37 
XMD17-26 760 ± 12 754  110 156  12 4.1  0.24 
(+)-JQ1 64  120 49.0 ± 2.4* 10.1  0.11 
aIC50 values were measured by AlphaScreenTM binding assay 
and reported as the average of 2 replicates ± SE. Experiments 
were conducted in Dana-Farber Cancer Institute. bIC50 values 
were measured by AlphaScreenTM binding assay and reported 
as the average of 4 replicates ± SD. Experiments were conduct-
ed in University of Oxford. cKd values were measured by ITC 
and reported as the average of 4 replicates ± SD. dΔTm values 
were measured by DSF and reported as the average of 3 repli-
cates ± SD. *The JQ1 Kd value is from a previous publication. 
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ty was confirmed in biochemical enzyme assays, where JWG-
071 showed little selectivity for ERK5 relative to LRRK2 and 
DCAMKL2 in vitro (1.2 and 2.5 folds respectively). Com-
pared to the previously published ERK5 tool compound 
XMD17-109 (ERK5-IN-1), JWG-071 has 2-fold improved 
ERK5 activity, and 10-fold improved BRD4 selectivity. Over-
all, these data show that JWG-071 will be a much-needed 
chemical probe for deconvoluting ERK5 and BRD4 pharma-
cology.  
Surprisingly, the cyclobutyl and cyclopentyl R1 substituted 
compounds JWG-069 and XMD17-26 exhibited strong bind-
ing to BRD4. These cyclic substitutions were also well toler-
ated by ERK5 and LRRK2, indicating that these are optimal 
R1 groups for achieving BRD/Kinase polypharmacology.  
The activities of corresponding analogs with 2-methoxy-4-
(4-methylpiperazin-1-yl) aniline tails against ERK5, LRRK2 
and BRD4 displayed a similar trend, although with slightly 
lower BRD4 binding, indicating that the activity difference is 
mainly due to the changes to interactions with the R1 substitu-
ent and the benzo[e]pyrimido- [5,4-b]diazepine-6(11H)-one 
core structure (Supplemental Table 2).  
In order to gain a structural understanding of this piece of 
the SAR, we determined crystal structures of BRD4 with the 
R1 analogs (Table 2, entries 2-5, Supplemental Table 1), and 
compared them to the structures with XMD11-50 and 
XMD17-26. The binding mode and key interaction with 
Asn140 is conserved among all analogs. Alkyl substitutions at 
the R1 position introduce additional steric restrictions, chang-
ing the angular configuration of the “butterfly-shaped” tricy-
clic core as seen in the structure of XMD17-26 (Figure 3A). 
Table 2. Activity profile of inhibitors with diazepinone scaffold    
 
Compound ID R1 R2 R3 X 
Biochemical 
IC50 (BRD4, 
µM)a 
Biochemical 
IC50 (BRD4, 
µM)b 
Enzymatic 
IC50 (ERK5, 
µM)c 
Enzymatic IC50 
(LRRK2, µM)d 
Viability IC50 
(BRD4, µM)e 
Cellular EC50 
(ERK5, µM)f 
Inhibitor  
classificationg 
Co-crystal 
(pdb number) 
XMD11-50 
(LRRK2-IN-1) 
Me Me Me N 0.703 ± 0.017 1.04 ± 0.18 
0.114 ± 
0.011 
0.0034 ± 
0.0017 
1.989 ± 0.299 0.16 ± 0.04 BRD4/LRRK2 
Roco4 
(4YZM)32 
BRD4 (5WA5)  
JWG-048 Et Me Me N 1.33 ± 0.05 2.41 ± 0.23 
0.173 ± 
0.037 
0.0044 ± 
0.0005 
2.625 ± 0.540 0.022 ± 0.004 LRRK2 BRD4 (5W55) 
 JWG-046 i-Pr Me Me N 4.59 ± 0.14 5.14 ± 0.59 
0.125 ± 
0.026 
0.054 ± 0.004 ND 0.014 ± 0.004 ERK5/LRRK2 BRD4 (6CD4) 
 JWG-071 s-Bu Me Me N 5.42 ± 0.18 6.31 ± 1.93 
0.088 ± 
0.005 
0.109 ± 0.014 >10 0.020 ± 0.003 ERK5/LRRK2 BRD4 (6CJ1) 
JWG-069 cyclobutyl Me Me N 0.201 ± 0.007 0.41 ± 0.01 
0.075 ± 
0.009 
0.021 ± 0.001 0.116 ± 0.001 0.019 ± 0.005 
BRD4/ERK5/
LRRK2 
BRD4 (6CIY) 
XMD17-26 cyclopentyl Me Me N 0.760 ± 0.012 0.75 ± 0.11 
0.082 ± 
0.009 
0.095 ± 0.010 0.664 ± 0.014 0.08 ± 0.02 
BRD4/ERK5/
LRRK2 
ERK5 (4B99)21 
BRD4 (5CD5) 
JWG-112 s-Bu H Me N 25.7 ± 1.8 >40 >10 1.59 ± 0.37 ND ND No activity  
JWG-049 i-Pr Me Et N 2.50 ± 0.07 3.53 ± 0.82 
0.069 ± 
0.007 
0.114 ± 0.011 ND 0.025 ± 0.007 ERK5/LRRK2  
JWG-114 i-Pr Me i-Pr N 0.862 ± 0.065 1.08 ± 0.13 
0.421 ± 
0.007 
0.235 ± 0.034 ND ND 
BRD4/weak 
LRRK2 
 
XMD17-109 
(ERK5-IN-1) 
cyclopentyl Me Et N 0.217 ± 0.008 0.68 ± 0.03 
0.162 ± 
0.006 
0.171 ± 0.030 ND 0.09 ± 0.03 
BRD4/ERK5/
LRRK2 
 
 JWG-047 cyclopentyl Me i-Pr N 0.135 ± 0.004 0.30 ± 0.05 
0.160 ± 
0.008 
0.296 ± 0.031 0.465 ± 0.012 0.032 ± 0.009 
BRD4/ERK5/
LRRK2 
BRD4 (6CIS) 
AX15836 SO2Me Me Et N >100 >40 
0.012 ± 
0.002 
0.942 ± 0.569 ND 0.036 ± 0.004 ERK5  
DFCI-2-208 Me Me Me C 5.21 ± 0.14 4.64 ± 0.65 >10 >10 ND ND No activity  
JWG-115 cyclopentyl Me i-Pr C 1.08 ± 0.05 1.10 ± 0.05 >10 > 3.3 ND ND BRD4 (weak)  
(+)-JQ-1  
 
  0.064  0.12  >10 >10 0.228  ND BRD4  
aIC50 values were measured by AlphaScreen
TM binding assay and reported as the average of 2 replicates ± SE. Experiments were 
conducted in Dana-Farber Cancer Institute. bIC50 values were measured by AlphaScreen
TM binding assay and reported as the aver-
age of 4 replicates ± SD. Experiments were conducted in University of Oxford. cIC50 values were measured by in vitro assay and 
reported as the average of 2 replicates ± SD. dIC50 values were measured using Adapta assay format (ThermoFisher Scientific) and 
reported as the average of 2 replicates ± SD. eIC50 were determined in 797 NUT-midline carcinoma cells by cell numbers using 
Cell Titer Glo and reported as the average of 3 replicates ± SD. fEC50 values were measured by EGF-stimulated autophosphoryla-
tion of ERK5 in Hela cells and reported as the average of 2 replicates ± SD. gConsidering that weak BET bromodomain inhibition 
has been shown to result in phenotypic responses, a BRD4 activity within 20 fold of JQ1 was defined as BET active.  0.2 µM was 
chosen as the  threshold for kinase activity. A 10-fold activity difference among kinases was considered selective. 
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Since co-crystal structures of XMD17-26 with ERK5 kinase 
(PDB: 4B99)21 and XMD11-50 with Roco4 kinase (Dictyoste-
lium disco homolog of LRRK2, PDB: 4YZM)32 have been 
solved previously, we were also able to examine differences 
between the BRD4/ligand complexes and kinase/ligand com-
plexes for these molecules. The crystal structure of JWG-069 
(R1 = cyclobutyl) in complex with BRD4-BD1 shows that 
additional hydrophobic interactions are formed by the R1-
group and the sidechain of Trp81. Such interactions are further 
stabilized by Pro82 as well as the aniline tail of the compound, 
as was observed in the XMD17-26 structure (R1 = cyclopen-
tyl, Figure 2B and 2C). However, such hydrophobic stacking 
interactions of the R1 group are not present in the ERK5/ 
XMD17-26 structure, leaving the ability to inhibit the kinases 
effectively unaltered when compared with simple acyclic alkyl 
R1-groups. Consistent with previously published results, a 
gradual decrease of inhibitory activity against LRRK2 was 
observed upon increasing the size of the R1-group.
19,20 Struc-
tural analysis of XMD11-50 with Roco4 kinase shows that the 
methyl group on R1 is accommodated by a small hydrophobic 
pocket formed by Leu99, Val107, and is very close to the P-
loop. Larger substitutions do not fit into this space, due to a 
steric clash with the P-loop. However, in ERK5, the P-loop 
swings upward and opens this space, enabling accommodation 
of larger substituents (Figure 3B). These structures provide 
insight into why LRRK2 activity is changed in response to 
substitution at the R1 position, whilst there is no change to 
ERK5 activity.  
The observations i) that the N-methyl amide group of the 
diazipinone ring fills the hydrophobic cavity of BRD4-BD1 
and ii) that the ACK probe XMD8-87 which lacks a methyl 
group at this position shows much weaker inhibition of BRD4-
BD1 encouraged us to explore the effect of N-methylation at 
the R3 position. Four pairs of compounds (R2=Me/H) with 
different R1 substitution were first compared (Supplemental 
Table 2). Compounds with R2=H show lower affinities for 
both BRD4 and ERK5 with the exception of ACK. The same 
phenomenon was observed for XMD11-50 (LRRK2 probe), 
XMD12-1 (Aurora A probe) and their pairs. These activity 
patterns indicate that the N-methyl amide pharmacophore is 
essential for both BRD4 and ERK5 binding. JWG-112, the 
hydrogen analog of the selective ERK5 inhibitor JWG-071, 
was also synthesized and tested. As expected, inhibitory activ-
ity toward both BRD4 and ERK5 decreased dramatically.  
The ligand bound BRD4 structures described above show 
that the methoxyphenyl moiety (R3) participates in bromo-
domain binding, and the kinase structures Roco4/XMD11-50 
and ERK5/XMD17-26 also show direct interaction between 
the kinase and this moiety. Therefore, we next investigated 
how substitution at the R3 position modulates protein selectivi-
ty (Table 2). Compounds with acyclic alkyl (JWG-046, 
JWG-049, and JWG-114) or cycloalkyl substitutents 
(XMD17-26, XMD17-109, and JWG-047) at the R3 position 
have been tested. Increasing the size of R3 slightly strength-
ened binding to BRD4, while decreasing inhibition of ERK5 
and LRRK2. The structure of JWG-047 with BRD4-BD1 
revealed a small shift at the isopropyloxyphenyl moiety com-
pared to the methoxyphenyl group of XMD17-26, resulting in 
an additional structural water participating in the ligand-
protein interaction and increased van de Waals interactions 
 
Figure 3. (A) Overlay of structures of XMD11-50 (green), JWG-048 (salmon), JWG-046 (orange), JWG-071(pink), JWG-069 
(cyan) and XMD17-26 (yellow) highlighting the different curvature of the diazipinone ring system and deviation of the tail. (B) 
Overlay of Roco4/XMD11-50 (pdb code 4YZM, top), and ERK5/XMD17-26 (pdb code 4B99, bottom), crystal structure reveal dif-
ferences in P-loop (red) conformation and explain observed R2 SAR. (C) Overlay of JWG-047 and XMD17-26 in complex with 
BRD4-BD1 reveal differences in local interactions and the presence of a new water molecule in the JWG-047 complex. 
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between the R3 isopropyl group and Gln85 (Figure 3C). We 
did not explore R3 substitution further because of its modest 
effect on binding. Ultimately, the variation of substituents at 
the three tested positions resulted in a dual kinase-
bromodomain inhibitor JWG-047 with BRD4 activity compa-
rable to JQ1 (2.2 – 2.5 fold less active than JQ1). 
Finally, we used the structural information to design BRD4 
selective inhibitors by modifying the scaffold. Since the nitro-
gen atom at the 3-position of the pyrimidine is known to be 
critical for kinase activity by forming a key hydrogen bond 
with the kinase hinge region, substituting the pyrimidine for a 
pyridine ring should result in a compound with much lower 
kinase activity and this is likely to hold true across the ki-
nome, rather than as a LRRK2/ERK5 specific effect.21,32 As 
expected, both DFCI-2-208 and JWG-115 lost activity 
against the kinase targets. However, their activity against 
BRD4 also decreased 4-8 fold compared to the pyrimidine 
analogs XMD11-50 and JWG-047, demonstrating pyrimidine 
core is favorable even for BRD binding (Table 2). JWG-115 
is a modestly potent (1 μM) BET-selective probe against the 
tested kinases ERK5/LRRK2.  
Different atropisomeric conformers bound to BRD4 and 
kinases. Strikingly, when comparing kinase and BRD4 co-
crystal structures, we observed that both XMD11-50 and 
XMD17-26 exhibited different conformations when bound to 
BRD4 than when bound to kinase targets (Figure 4A, 4B, 
PDB: 4YZM and 4B99). These conformers arise due to the 
axial chirality about the C-N bond in the rotationally hindered 
7-membered ring (Figure 4C). In the kinase structures the 
(Ra) conformer is observed, whereas in the BRD4 structures 
solved here the (Sa) conformer is observed.  
Table 3. Relationship between R1 and observed coalescence temperature, calculated half-life, and energy barrier of 
interconversion. 
 
Compound ID 
Corresponding 
parent molecule 
Structure R1 Tco (oC)  Calc t1/2 rac (s) 
Calc ∆Erac  
(kcal/mol) 
JWG-088 
XMD11-50 
(LRRK2-IN-1) 
 
Me <25 - - 
JWG-091 
JWG-048 
 
Et <25 - - 
JWG-082 JWG-046 i-Pr 47 0.07 16.3 
 JWG-089 JWG-069 cyclobutyl 100 2.66 18.4 
JWG-090 XMD17-26 cyclopentyl 68 0.35 17.2 
 JWG-098 AX15836 -SO2Me 120 31.0 19.9 
 JWG-071  As in table 2 s-Bu 60 0.04 15.9 
 
 
Figure 4. View showing different conformers bound to BRD4 and Kinase; (A) XMD11-50 bound to BRD4-BD1 (upper panel) and 
Roco4, pdb code 4YZM (lower panel). (B) XMD17-26 bound to BRD4-BD1 (upper panel) and ERK5, pdb code 4B99 (lower pan-
el). (C) Axis of chirality can rotate to generate two different conformations of the tricyclic ring system. 
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As we did not observe separation of entries 1 – 6, Table 2, 
by chiral HPLC separation, we determined t1/2 
rac using NMR 
spectroscopy, in order to characterize whether these molecules 
exist as conformers or separable atropisomers. When the half-
life (t1/2) for interconversion of the two conformations is great-
er than 1000 seconds at room temperature, which corresponds 
to an interconversion energy barrier greater than 20 kcal/mol, 
the molecules exist as a mixture of two distinct atropisomers 
and each atropisomer can, in theory, be isolated. 33,34 In this 
case, each atropisomer should be evaluated separately for its 
ability to bind to BRD4, ERK5 and LRRK2. We anticipated 
the t1/2 in this series to be influenced by the steric bulk of R1. 
In order to generate diasteromers that exhibit distinct 1H NMR 
resonances which would enable characterization of the t1/2 of 
racemization using variable temperature 1H NMR experiments 
we synthesized the corresponding (-)-menthol derivatives of 
R1 variants. Considering menthol and methyl-4-(piperidine-4-
yl) piperazine moieties at the tail position are likely to have 
little effect on the 7-membered ring conformation, we hypoth-
esized that the parent molecules have similar interconversion 
temperatures as (-)-menthol derivatives. JWG-071 (R1 = sec-
butyl) contains a stereocenter and the potential for four dia-
stereomers. In this molecule we could directly observe two 
sets of NMR signals, therefore we could measure the coales-
cence temperature directly (60 oC) without needing to resort to 
the preparation of chiral menthol esters.  
At room temperature, JWG-088 and JWG-091 exhibited 
only a single set of NMR resonances indicating that they are 
achiral compounds whose conformers interconvert rapidly. 
Once R1 was increased, the compounds exhibited two sets of 
resonances with equal abundance (JWG-082, JWG-089, and 
JWG-090). Hence, we performed variable temperature 1H 
NMR experiments from 25 °C to 120 °C in DMSO-d6 (Sup-
plemental Spectra) and observed that the coalescence tempera-
tures of isopropyl, cyclobutyl, and cyclopentyl analogs were 
47 °C, 100 °C and 68 °C respectively (Table 3 and Supple-
mental Spectra). During the course of this work, another group 
reported modification of XMD17-109 to generate AX15836 
that possess excellent ERK5 activity and selectivity against 
BRD4.26 We independently synthesized and confirmed the 
activity and selectivity of this inhibitor (Table 2). We also 
synthesized the corresponding menthol ester JWG-098 (R1 = 
methylsulfonyl) and observed its coalescence temperature to 
be 120 °C (Table 3).  
We next calculated the half-lives and energy barriers for in-
terconversion of the compounds. As we expected, the R1 sub-
stituent affected the energy barrier and rate of interconversion 
between conformers, and this conclusion was supported by 
quantum mechanical analysis of the ground and transition 
states of the conformers of XMD11-50 and XMD17-26 (Ta-
ble 3, Supplemental Figure 5). Nevertheless, all analogs had 
energy barriers lower than 20 kcal/mol, indicating that these 
analogs interconverted with half-lives measured in seconds 
and can therefore not be separated at room temperature.  
In the absence of separable atropisomers, we used docking 
studies to explore the observed isomer preferences of kinases 
and bromodomains. Using the dual kinase-bromodomain tar-
getting analogs XMD11-50 and XMD17-26, the Ra and Sa 
conformations of each compound were frozen and docked into 
apo BRD4 bromodomain and ERK5 kinase domain structures. 
For both compounds, low energy solutions were found for the 
Sa confomers docked into BRD4, but no solutions were found 
for the Ra conformer. Similarly, low energy solutions were 
found for the Ra conformer docked into ERK5, but no solu-
tions were found for the Sa confomer, indicating that the ob-
served preferences in crystallography are due to differing 
binding affinities of the conformers for each target (Supple-
mental Figure 6).We anticipate that compounds that intro-
duce further steric constraints to the diazepine core might pos-
sess atropisomers that could be separated. In contract to JWG-
071, JWG-112 displays only one set of NMR resonances at 
room temperature, suggesting substitution at R2 position also 
increases steric hindrance and can be a further modification 
spot. Our computational analysis indicates that separable atro-
pisomers may display kinase selectivity (Ra) or BRD selectivi-
ty (Sa) dependent on their chirality. 
Conclusions. In this paper, we identify a new class of dual 
kinase-bromodomain inhibitors with a shared hetero-tricyclic 
core. Through SAR studies and complementary structural 
studies, we defined a blueprint for tuning in or out kinase or 
bromodomain activity (Figure 5). This resulted in identifica-
tion of an ERK5 selective chemical probe (JWG-071) and a 
BRD4 selective probe (JWG-115) as well as inhibitors with 
rationally designed polypharmacology (JWG-047, JWG-
069). We also observed different conformational isomers in 
bromodomain vs kinase X-ray structures, leading to investiga-
tion of the atropisomeric properties of this scaffold. Atro-
pisomerism has previously been exploited to improve the sub-
family selectivity of kinase inhibitors.35 In this work we report 
the first example of different protein target classes distinguish-
ing between atropisomeric conformers. Since the 7-membered 
diazepine ring is widely used in drug development and exists 
in natural products36, this newly discovered contribution of 
atropisomers to protein target selectivity is a highly relevant 
topic warranting further investigation. Future work will focus 
on synthesis of enantiomerically pure analogs with slower 
interconversion rates to evaluate the binding ability to BRD4 
and kinases of each isomer. 
 
METHODS  
Protein Preparation. The first bromodomain of Brd4 
(BRD4-BD1, residues 42-168) was subcloned into a modified 
pET-15b(+) vector with an N-terminal His6 tag followed by a 
Tobacco Etch Virus cleavage site. The encoded protein was 
expressed in the E. coli BL21(DE3) strain. E. coli cells trans-
formed with the vector were grown 4 hours at 37 °C to an 
OD600 of 1.0, in 1 liter LB media containing ampicillin (0.1 
mg/ml). After 0.1 mM IPTG induction at 20 °C, cells were 
cultured overnight, and collected by centrifugation at 4,000 g. 
The pellet was suspended in 40 ml lysis buffer containing 50 
mM HEPES, pH 7.4, 500 mM NaCl, 5 mM -
 
Figure 5. SAR rules for benzo[e]pyri(mi)do-[5,4-b]diazepine-
6(11H)-one activity against BRD4 and ERK5 targets. 
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mercaptoethanol, and 1 mM PMSF. Cells were lysed on ice by 
sonication and cell debris was precipitated by centrifugation at 
15,000 g for 30 minutes. BRD4-BD1 was purified by affinity 
chromatography on an Ni-NTA agarose column (Qiagen), 
using an elution buffer of 50 mM HEPES, pH 7.4, 500 mM 
NaCl, 5 mM  -mercaptoethanol, and 250 mM of imidazole. 
After overnight TEV cleavage of the His6-tag, the cleaved tag 
was captured on affinity resin, and BRD4-BD1 was then puri-
fied to homogeneity by gel filtration before concentration to 
roughly 15 mg/ml in storage buffer (25mM HEPES, pH 7.4, 
and 150 mM NaCl). 
Bromodomain BRD4-1 AlphaScreen binding assay in 
Dana-Farber Cancer Institute. Assays were performed with 
minor modifications from the manufacturer’s protocol (Perkin 
Elmer, USA). All reagents were diluted in AlphaScreenTM 
buffer (50 mM HEPES, 150 mM NaCl, 0.01% v/v Tween-20, 
0.1% w/v BSA, pH = 7.4). After addition of Alpha beads to 
master solutions, all subsequent steps were performed under 
low light conditions. A 2x solution of components with final 
concentrations of His-Brd4(1) at 0.020 µM, Ni-coated Accep-
tor Bead at 10 µg/ml, and biotinylated-(+)-JQ1 at 0.010 µM 
were added in 10 µL to 384-well plates (AlphaPlate-384, 
PerkinElmer) using an EL406 liquid handler (Biotek, USA). 
Plates were spun down at 1000 rpm. A 10-point 1: 3 serial 
dilution of compounds in DMSO was prepared at 200x the 
final concentration. 100 nL of compound from these stock 
plates were added by pin transfer using a Janus Workstation 
(PerkinElmer). A 2x solution of streptavidin-coated donor 
beads with a final concentration of 10 µg/ml was added in a 10 
µL volume. The plates were spun down again at 1000 rpm and 
sealed with foil to prevent light exposure and evaporation. The 
plates were then incubated at room temperature for 1 h and 
read on an Envision 2104 (PerkinElmer) using the manufac-
turer’s protocol. IC50 values were calculated using a 4-
parameter logistic curve in Prism 6 (GraphPad Software, 
USA) after normalization to DMSO-treated negative control 
wells (0.2% DMSO, v/v). 
Bromodomain BRD4-1 AlphaScreen binding assay in 
University of Oxford. Assays were performed as described 
previously with minor modifications from the manufacturer’s 
protocol (PerkinElmer, USA). All reagents were diluted in 25 
mM HEPES, 100 mM NaCl, 0.1 % BSA, pH 7.4 and 0.05 % 
CHAPS and allowed to equilibrate to room temperature prior 
to addition to plates. A 11-point 1:2.0 serial dilution of the 
ligands was prepared on low-volume 384-well plates (Prox-
iPlateTM-384 Plus, PerkinElmer, USA) using LabCyte Eco 
liquid handler. Plates filled with 5 uL of the assay buffer fol-
lowed by 7 uL of biotinylated peptide [H-
YSGRGKacGGKacGLGKacGGAKacRHRK(Biotin)-OH and 
His-tagged protein to achieve final assay concentrations of 25 
nM. Plates were sealed and incubated for a further 60 minutes, 
before the addition of 8 μl of the mixture of streptavidin-
coated donor beads (12.5 μg/ml) and nickel chelate acceptor 
beads (12.5 μg/ml) under low light conditions. Plates were 
foil-sealed to protect from light, incubated at room tempera-
ture for 60 minutes and read on a PHERAstar FS plate reader 
(BMG Labtech, Germany) using an AlphaScreen 680 excita-
tion/570 emission filter set. IC50 values were calculated in 
Prism 6 (GraphPad Software, USA) after normalization 
against corresponding DMSO controls and are given as the 
final concentration of compound in the 20 μl reaction volume. 
Isothermal Titration Calorimetry. Experiments were per-
formed using a MicroCal ITC200 calorimeter (GE 
Healthcare). All experiments were carried out at 25 C 
with1000 RPM stirring speed, in a buffer containing 25mM 
HEPES pH7.5 and 100 mM NaCl. The injection syringe was 
loaded with a solution of the protein sample at 200 uM con-
centration and the cell was filled with compound at 20uM 
concentration. Single binding site model in Origin software 
(OriginLab, Northampton MA USA) was employed to calcu-
late dissociation constants and thermodynamic parameters. 
Protein Stability Assay. Differential scanning fluorimetry 
(DSF) was used to measure stabilization of BRD4-BD1 at 2 
M concentration in the presence of 10 M compound in a 
volume of 20 l. SYPRO Orange (Molecular Probes) was 
included (diluted 1:1000) as the fluorescence probe, with exci-
tation and emission wavelength set to 465nm and 590nm, re-
spectively. Fluorescence measurements were taken regularly 
over a thermal gradient from 25 C to 95 C using a ramp rate 
of 3 C per minute. The data were plotted using non-linear 
least squares fitting, and temperature shifts were calculated as 
the difference between the transition midpoints of the protein 
with and without compounds. 
ERK5 kinase activity in vitro assay. A 40 µL reaction 
mixture was prepared containing 200 ng of pure active ERK5 
and the indicated amount of inhibitor in 50 mM Tris-HCl, pH 
7.5, 0.1 mM EGTA, 1 mM 2-mercaptoethanol. The reaction 
was initiated by adding 10 mM magnesium acetate, and 50 
µM [γ-32P]-ATP (500 cpm/pmol) and 200 µM PIMtide 
(ARKKRRHPSGPPTA) as substrates. Assays were carried out 
for 20 min at 30 oC, terminated by applying the reaction mix-
ture onto p81 paper and the incorporated radioactivity meas-
ured as described previously. The expression and purification 
of ERK5 was carried out as described previously. 37 
LRRK2 kinase activity in vitro assay. An in vitro assay of 
LRRK2 kinase activity was performed in Adapta kinase assay 
format at Thermo Fisher Scientific (Madison, WI) using the 
SelectScreen Kinase Profiling Service. All protocols are avail-
able from the Thermo Fisher Scientific website. 
797 NMC Cell Viability Assay. Cells were plated in a 96-
well plate at a density of 5,000 cells/well and incubated for 3 
days in the presence of various concentration of compounds or 
DMSO. Relative cell numbers were determined in 6 replicates 
using Cell Titer Glo (Promega, Madison, WI) according to the 
manufacturer’s instructions. 
Cellular assay of ERK5.  Human HeLa cells were serum 
starved overnight followed by treatment with the indicated 
inhibitor for one hour. Cells were then stimulated with EGF 
(50 ng/mL) for 20 min and harvested in RIPA buffer (1X PBS, 
1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mg/ml 
PMSF and 1mM sodium orthovanadate). Proteins from total 
cell lysates were resolved by 6% sodium dodecyl sulfate 
(SDS)-polyacrylamide gel electrophoresis (PAGE), transferred 
to nitrocellulose membrane, blocked in 5% nonfat milk, and 
blotted with anti-ERK5 antibody (Cell Signaling Technology, 
Boston, MA). Active ERK5 activity was calculated by moni-
toring the amount of retarded, autophosphorylated band in the 
immunoblots, as described elsewhere. 
Crystallization and Data Collection. BRD4-BD1 com-
plexes were crystallized using the hanging drop vapor diffu-
sion method at room temperature, using either co-
crystallization or soaking methods. For soaking experiments, 
inhibitor-free crystals were first obtained in a drop with equal 
volumes of BD1 at 4 mg/ml and a precipitant solution contain-
ing 100mM sodium nitrate, 5% ethylene glycol, and 18% 
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(w/v) PEG3350, as precipitant. Rod-like crystals obtained in 
10 days were transferred and soaked in the same crystalliza-
tion buffer pulsing compounds at 0.5 mM concentration for 5-
7 days. For co-crystallization experiments, protein was first 
incubated with compounds at molar ratio of 1:3 and then 
mixed with the same precipitant solution as in soaking exper-
iments. For data collection, a single crystal was picked and 
flash-frozen with a precipitant solution containing 20% (v/v) 
glycerol. Diffraction data for each complex were collected 
from a flash-cooled crystal at 100 °K using the NE-CAT 
24ID-C or 24ID-E beam lines at Argonne National Laborato-
ry. Data were processed, integrated, and scaled using 
HKL2000 (Otwinowski, Z., and Minor, W. (1997)). 
Structure determination and refinement. Structures of 
BRD4-BD1 complexes were solved by molecular replacement 
(MR) in Phenix38 using the BD1-UMB32 structure (PDB 
4WIV) as a search model. Structure refinement was carried 
out using conjugate-gradient energy minimization, torsion-
constrained molecular dynamics simulated annealing, group B 
factor refinement, and individual B factor refinement proto-
cols in Phenix with 5% of the reflections omitted for free R 
factor calculation. Electron density peaks above 3σ in differ-
ence Fourier maps were assigned to water molecules in later 
refinement stages if they had reasonable geometry in relation 
to hydrogen bond donors or acceptors and their B-factors did 
not rise above 50 Å2 during subsequent refinement. Model 
building was performed in Coot guided by σA-weighted 2Fo-
Fc and Fo-Fc maps and composite omit maps. 
Kinome Profiling. Kinome profiling was performed using 
KinomeScan ScanMAX at compound concentration of 1μM. 
Data was reported in Supplemental data. Protocols are availa-
ble from DiscoverX.  
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